Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FONDO-LOW: Olanzapine Dosing for CINV in Myeloma
NCT06588413Phase 3Recruiting
- Sponsor
- Augusta University
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Augusta University. Primary endpoint: Complete Response. Started Sep 2024; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06588413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588413.